Deciphering the immunoboosting potential of macro and micronutrients in COVID support therapy

Batiha, Gaber El‐Saber; Al-Gareeb, Ali I; Qusti, Safaa; Alshammari, Eida M.; Kaushik, Deepak; Verma, Ravinder; Al-Kuraishy, Hayder M

doi:10.1007/s11356-022-20075-7

Cited by 13 publications

(10 citation statements)

References 164 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Syncytiotrophoblast cells regulate feto-maternal nutrient supply and gas exchange [ 55 ]. Therefore, a higher expression of placental ACE2 during pregnancy increases the risk of SARS-CoV2 infections during pregnancy and increases the risk of VT [ 39 , 56 , 105 , 106 ].…”

Section: Discussionmentioning

confidence: 99%

Pregnancy and COVID-19: high or low risk of vertical transmission

et al. 2022

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 19 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome 2 (SARS-CoV-2). Throughout the pandemic, evidence on the effects of COVID-19 during pregnancy has been inadequate due to the limited number of studies published. Therefore, the objective of this systematic review was to evaluate current literature regarding the effects of COVID-19 during pregnancy and establish pregnancy outcomes and vertical and perinatal transmission during pregnancy. Multiple databases were searched, including Embase, Medline, Web of Science, Scopus, and Cochrane Central Register of Control Clinical Trials, using the following keywords: [Pregnancy] AND [COVID-19 OR SARS-CoV-2 OR nCoV-19] OR [Perinatal transmission, Vertical transmission (VT), Pregnancy complications], [Pregnancy] AND [Hyperinflammation OR Cytokine storm]. We excluded in vitro and experimental studies, but also ex-vivo and animal study methods. To exclude the risk of bias during data collection and interpretation, all included studies were peer-reviewed publications. This review is estimated to tabulate the study intervention characteristics and compare them against the planned groups for each synthesis. Our findings showed that pregnant women are commonly susceptible to respiratory viral infections and severe pneumonia due to physiological immune suppression and pregnancy-induced changes. VT of SARS-CoV-2 infection during pregnancy is associated with a great deal of controversy and conflict. However, there is still no robust clinical evidence of VT. Furthermore, the clinical presentation and management of COVID-19 during pregnancy are nearly identical to those of non-pregnant women. Finally, chloroquine and remdesivir are the only two drugs evaluated as adequate for the management of COVID-19 during pregnancy.

show abstract

Section: Discussionmentioning

confidence: 99%

Pregnancy and COVID-19: high or low risk of vertical transmission

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In its clinical perspective, IVN might be a pioneer drug in attenuating cardiotoxicity, mainly in patients with heart failure, arrhythmias, and malignancies treated by DXR. It has been shown that unlike β-blockers, IVN does not decrease ventricular force (Su et al 2020 ; Al-Kuraishy et al 2021b , 2022c , d ; Lawal et al 2021 ) and can also reduce COVID-19-induced cardiovascular complications due to its anti-inflammatory and antioxidant properties (Al-Kuraishy et al 2021c , 2022e ; Batiha et al 2021 , 2022 ). In addition, IVN facilitates a pleiotropic cardioprotective effect against isoproterenol-induced acute cardiac injury by increasing the ventricular fibrillation threshold (Simko et al 2021 ).…”

Section: Discussionmentioning

confidence: 99%

The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument

et al. 2022

Self Cite

View full text Add to dashboard Cite

This study investigated the potential role of ivabradine (IVN) in the attenuation of doxorubicin (DXR)-induced cardiotoxicity in rats. A total of 28 Swiss-Albino male mice were used, divided into four equal groups: the negative control did not receive any agents ( n = 7), the DXR group received a single dose of DXR 20 mg/kg ( n = 7), the treated group A was pretreated with IVN 5 mg/kg plus DXR ( n = 7), and the treated group B was pretreated with IVN 10 mg/kg plus DXR ( n = 7). The duration of this study was 10 days. Inflammatory biomarkers, including tumor necrosis factor alpha (TNF-α), lactate dehydrogenase (LDH), malondialdehyde (MDA), and cardiac troponin (cTn-I) serum levels were measured. TNF-α, LDH, MDA, and cTn-I serum levels were higher in the DXR-treated mice compared with the control ( P ˂0.01). IVN produced a dose-dependent effect in the reduction of MDA and cTn-I compared to DXR-treated mice ( P ˂0.05). Our findings suggest that IVN is an effective agent in mitigating DXR-induced cardiotoxicity due to its anti-inflammatory and antioxidant effects. IVN illustrated a dose-dependent effect in the attenuation of DXR-induced cardiotoxicity through inhibition of lipid peroxidation and cardiomyocyte injury.

show abstract

“…Furthermore, the GDF15 was implicated in the pathogenesis of anemia by inhibiting the expression of hepcidin. However, hypoxia and anemia activate the expression and synthesis of GDF15 [ 42 , 43 ]. Lower hepcidin serum level is linked with COVID-19 severity and mortality [ 44 , 45 ].…”

Section: Growth Differentiation Factor 15 and Covid-19mentioning

confidence: 99%

The Potential Role of Growth Differentiation Factor 15 in COVID-19: A Corollary Subjective Effect or Not?

et al. 2022

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is primarily caused by various forms of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) variants. COVID-19 is characterized by hyperinflammation, oxidative stress, multi-organ injury (MOI)-like acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Different biomarkers are used in the assessment of COVID-19 severity including D-dimer, ferritin, lactate dehydrogenase (LDH), and hypoxia-inducible factor (HIF). Interestingly, growth differentiation factor 15 (GDF15) has recently become a potential biomarker correlated with the COVID-19 severity. Thus, this critical review aimed to determine the critical association between GDF15 and COVID-19. The perfect function of GDF15 remains not well-recognized; nevertheless, it plays a vital role in controlling cell growth, apoptosis and inflammatory activation. Furthermore, GDF15 may act as anti-inflammatory and pro-inflammatory signaling in diverse cardiovascular complications. Furthermore, the release of GDF15 is activated by various growth factors and cytokines including macrophage colony-stimulating factor (M-CSF), angiotensin II (AngII) and p53. Therefore, higher expression of GDF15 in COVID-19 might a compensatory mechanism to stabilize and counteract dysregulated inflammatory reactions. In conclusion, GDF15 is an anti-inflammatory cytokine that could be associated with the COVID-19 severity. Increased GDF15 could be a compensatory mechanism against hyperinflammation and exaggerated immune response in the COVID-19. Experimental, preclinical and large-scale clinical studies are warranted in this regard.

show abstract

Deciphering the immunoboosting potential of macro and micronutrients in COVID support therapy

Cited by 13 publications

References 164 publications

Pregnancy and COVID-19: high or low risk of vertical transmission

Pregnancy and COVID-19: high or low risk of vertical transmission

The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument

The Potential Role of Growth Differentiation Factor 15 in COVID-19: A Corollary Subjective Effect or Not?

Contact Info

Product

Resources

About